MCF Advisors
XBI icon

MCF Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MCF Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-100
Closed -$15.8K – 1311
2026
Q2 		$15.8K Buy
+100
New +$13.5K ﹤0.01% 951
2026
Q1 		– Sell
-375
Closed -$45.7K – 1407
2025
Q4 		$45.7K Buy
+375
New +$43K ﹤0.01% 531
2018
Q2 		– Sell
-43
Closed -$4K – 500
2018
Q1 		$4K Hold
43
– – ﹤0.01% 391
2017
Q4 		$4K Hold
43
– – ﹤0.01% 394
2017
Q3 		$4K Hold
43
– – ﹤0.01% 412
2017
Q2 		$3K Buy
+43
New +$3.05K ﹤0.01% 429

Other funds holding XBI

STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Annex Advisory Services
Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return
MIRAE ASSET SECURITIES (USA) INC.
MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.72% 1-Year Est. Return
Moss Adams Wealth Advisors
Moss Adams Wealth Advisors Seattle, Washington $1.53B AUM 19.03% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return
Parkway Wealth Management
Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return
Weatherly Asset Management
Weatherly Asset Management Del Mar, California $1.42B AUM 33.31% 1-Year Est. Return
L. Roy Papp & Associates
L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return
Madrona Financial Services
Madrona Financial Services Everett, Washington $646M AUM 23.24% 1-Year Est. Return

MCF Advisors's XBI Position: Q3 2026 in Review

MCF Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2026, closing a stake of 100 shares — an estimated $15.8K sold.

MCF Advisors first reported a position in XBI in Q2 2017 and held it in 6 quarters. The position peaked at $45.7K in Q4 2025. 375 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • MCF Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2026 after selling out during the quarter.
  • MCF Advisors sold 100 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $15.8K.
  • MCF Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 6 quarters.
  • MCF Advisors's State Street SPDR S&P Biotech ETF position peaked at $45.7K in Q4 2025.
  • 375 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on MCF Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.